1. Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects.
- Author
-
Li, Yue-Qi, Yan, Zheng-Yu, Zhang, Hong-Wen, Sun, Lu-Ning, Jiao, Hui-Wen, Wang, Mei-Feng, Yu, Li-Yuan, Yu, Lei, Yuan, Zi-Qing-Yun, Meng, Ling, and Wang, Yong-Qing
- Subjects
- *
DRUG therapy , *CHINESE people , *DRUG tolerance , *INJECTIONS , *SAFETY , *PROTON pump inhibitors , *LANSOPRAZOLE - Abstract
Purpose: This study was conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy subjects. Methods: Dexlansoprazole (20-90 mg) or lansoprazole (30 mg) was administrated intravenously to healthy male and female volunteers. All the subjects were sampled for pharmacokinetic (PK) analysis and 64 of them were monitored for 24-h intragastric pH prior to and after administration in the pharmacodynamic (PD) study. Results: Maximum plasma concentration (C) and area under the concentration-time curve (AUC) for dexlansoprazole injection was dose-proportional over the range of 20-90 mg following a single intravenous administration. Total clearance and half-life (t) was independent of dose, and ranged from 4.69 L/h to 5.85 L/h and from 1.24 h to 2.17 h, respectively. A single dose of dexlansoprazole (30 mg) resulted in higher gastric pH compared to that of lansoprazole, evidenced by a mean 24-h gastric pH of 6.1 ± 1.2 (lansoprazole: 5.4 ± 1.1) and 24-h gastric pH > 6 post drug dose holding time of 64.2 ± 21.0% (lansoprazole: 49.5 ± 21.5%). Conclusion: Dexlansoprazole injection was safe and well tolerated for up to 5-day repeated intravenous administration dose of 30 mg. The recommended dosage for dexlansoprazole injection is 30 mg for an adequate gastric acid control. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF